Viridian Therapeutics, Inc.
VRDN
$30.43
-$1.02-3.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -301.97M | -344.06M | -308.32M | -269.95M | -257.08M |
| Total Depreciation and Amortization | 863.00K | 1.18M | 1.21M | 1.24M | 1.57M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.00M | 28.38M | 26.66M | 26.79M | 43.78M |
| Change in Net Operating Assets | -57.86M | 5.44M | 701.00K | 9.60M | 14.75M |
| Cash from Operations | -325.97M | -309.06M | -279.75M | -232.32M | -196.99M |
| Capital Expenditure | -369.00K | -535.00K | -597.00K | -511.00K | -445.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 239.31M | 28.73M | 15.05M | -228.14M | -335.00M |
| Cash from Investing | 238.94M | 28.20M | 14.46M | -228.65M | -335.45M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 58.08M | 282.19M | 281.64M | 459.68M | 557.39M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 0.00 | 25.00M | 25.00M | 25.00M | 101.19M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.73M | -16.67M | -16.77M | -26.94M | -37.43M |
| Cash from Financing | 56.36M | 290.52M | 289.87M | 457.74M | 621.15M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.67M | 9.66M | 24.57M | -3.23M | 88.72M |